Keywords
Eosinophilic ascites
Initial symptoms
Diagnosis
Treatment
Categories
Abstract
Introduction: Hypereosinophilic syndrome is a rare condition characterised by a high number of blood eosinophils, accompanied by tissue infiltration and associated symptoms. Currently, this term is reserved solely for idiopathic cases; however, it is a diagnosis of exclusion that requires the prior ruling out of a large number of conditions, with particular emphasis on haematological neoplasms. Case report: We present a patient who presented with mild ascites, accompanied only by hypereosinophilia, in whom a pleural effusion and concomitant pericarditis were subsequently discovered. A screening process was carried out to identify conditions presenting with these characteristics, and the patient was ultimately diagnosed with hypereosinophilic syndrome, showing a rapid response to corticosteroid treatment. Discussion: This case illustrates the variability of symptoms associated with this condition, not identifying similar cases to the one presented, alongside the extensive differential diagnosis required to diagnose this syndrome.
References
Gigon L, Fettrelet T, Yousefi S, Simon D, Simon HU. Eosinophils from A to Z. Allergy. 2023 Jul;78(7):1810-1846. doi: 10.1111/all.15751. Epub 2023 May 7. PMID: 37102676.
Klion AD. Approach to the patient with suspected hypereosinophilic syndrome. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):47-54. doi: 10.1182/hematology.2022000367. PMID: 36485140; PMCID: PMC9821533.
Shomali W, Gotlib J. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024 May;99(5):946-968. doi: 10.1002/ajh.27287. Epub 2024 Mar 29. PMID: 38551368.
Rosa SC, Manuel JM, Gadea HB, Lorena H. Síndrome hipereosinofílico idiopático con presentación como abdomen agudo: a propósito de un caso. DOI: 10.1016/j.gastrohep.2020.12.014
Florence R, Amy DK, Peter FW. Hypereosinophilic syndromes: Clinical manifestations, diagnosis, and classification. Uptodate. Mar 19, 2026.
Valent P, Klion AD, Roufosse F, Simon D, Metzgeroth G, Leiferman KM, Schwaab J, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Hoermann G, Haferlach T, Moriggl R, George TI, Akin C, Bochner BS, Gotlib J, Reiter A, Horny HP, Arock M, Simon HU, Gleich GJ. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. Allergy. 2023 Jan;78(1):47-59. doi: 10.1111/all.15544. Epub 2022 Oct 19. PMID: 36207764; PMCID: PMC9797433.
Longhino D, Spinelli I, Fianchi F, Castri F, Ianiro G, Ponziani FR, Caruso C, Buonomo A, Antonio G, Aruanno A. Eosinophilic ascites and eosinophilic gastrointestinal diseases. Eur Ann Allergy Clin Immunol. 2025 Sep 12. doi: 10.23822/EurAnnACI.1764-1489.412. Epub ahead of print. PMID: 40948021.
Belfeki N, Ghriss N, Zayet S, El Hedhili F, Moini C, Lefevre G. Successful Introduction of Benralizumab for Eosinophilic Ascites. Biomedicines. 2024 Jan 6;12(1):117. doi: 10.3390/biomedicines12010117. PMID: 38255222; PMCID: PMC10812909.
Caminati M, Brussino L, Carlucci M, Carlucci P, Carpagnano LF, Caruso C, Cosmi L, D'Amore S, Del Giacco S, Detoraki A, Di Gioacchino M, Matucci A, Mormile I, Granata F, Guarnieri G, Krampera M, Maule M, Nettis E, Nicola S, Noviello S, Pane F, Papayannidis C, Parronchi P, Pelaia G, Ridolo E, Rossi FW, Senna G, Triggiani M, Vacca A, Vivarelli E, Vultaggio A, de Paulis A. Managing Patients with Hypereosinophilic Syndrome: A Statement from the Italian Society of Allergy, Asthma, and Clinical Immunology (SIAAIC). Cells. 2024 Jul 11;13(14):1180. doi: 10.3390/cells13141180. PMID: 39056762; PMCID: PMC11274683.
Pinte L, Baicus C. Causes of eosinophilic ascites - A systematic review. Rom J Intern Med. 2019 Jun 1;57(2):110-124. doi: 10.2478/rjim-2018-0041. PMID: 30864403.
Peter FW, Amy DK, Florence R. Approach to the patient with elevated eosinophil counts. Uptodate. Jan 20, 2026.
Requena G, van den Bosch J, Akuthota P, Kovalszki A, Steinfeld J, Kwon N, Van Dyke MK. Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review. J Allergy Clin Immunol Pract. 2022 Aug;10(8):2125-2134. doi: 10.1016/j.jaip.2022.03.034. Epub 2022 Apr 22. PMID: 35470096.
P.U. Ogbogu, B.S. Bochner, J.H. Butterfield, G.J. Gleich, J. Huss-Marp, J.E. Kahn, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapyJ Allergy Clin Immunol, 124 (2009). https://doi.org/10.1016/j.jaci.2009.09.022.
Wilkins HJ, Crane MM, Copeland K, Williams WV. Hypereosinophilic syndrome: an update. Am J Hematol. 2005 Oct;80(2):148-57. doi: 10.1002/ajh.20423. PMID: 16184589.
Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Dis. 2007 Sep 11;2:37. doi: 10.1186/1750-1172-2-37. PMID: 17848188; PMCID: PMC2045078.
Roufosse F, Kahn JE, Rothenberg ME, Wardlaw AJ, Klion AD, Kirby SY, Gilson MJ, Bentley JH, Bradford ES, Yancey SW, Steinfeld J, Gleich GJ; HES Mepolizumab study group. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020 Dec;146(6):1397-1405. doi: 10.1016/j.jaci.2020.08.037. Epub 2020 Sep 18. PMID: 32956756; PMCID: PMC9579892.
Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK, Beck LA, Boyce JA, Filipovich AH, Villanueva JM, Sutton SA, Assa'ad AH, Rothenberg ME. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol. 2004 Jan;113(1):115-9. doi: 10.1016/j.jaci.2003.10.049. Epub 2003 Dec 12. PMID: 14699394.
Mora E, Fox ML, Lemes A, Velasco B, Hernández-Rivas JM. Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence. Front Immunol. 2025 Nov 14;16:1704077. doi: 10.3389/fimmu.2025.1704077. PMID: 41322417; PMCID: PMC12660071.
Klion A. Hypereosinophilic syndrome: approach to treatment in the era of precision medicine. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):326-331. doi: 10.1182/asheducation-2018.1.326. PMID: 30504328; PMCID: PMC6245960.
Ogbogu PU, Roufosse F, Akuthota P, Kuna P, Groh M, Reiter A, Yokota A, Siddiqui SH, Mutsaers PGNJ, Li B, Khoury P, Bahadori LM, Bednarczyk A, Bouma G, Brooks LG, Ferreira J, Grindebacke H, Ho CN, Jain P, Palmer RL, Jison ML, Klion AD; NATRON study group. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. 2026 Jun;32(6):2017-2025. doi: 10.1038/s41591-026-04315-8. Epub 2026 Mar 31. Erratum in: Nat Med. 2026 Jun;32(6):2319. doi: 10.1038/s41591-026-04425-3. PMID: 41917160; PMCID: PMC13278967.
Boussir H, Ghalem A, Ismaili N, El Ouafi N. Eosinophilic myocarditis and hypereosinophilic syndrome. J Saudi Heart Assoc. 2017 Jul;29(3):211-213. doi: 10.1016/j.jsha.2016.11.001. Epub 2016 Nov 17. PMID: 28652675; PMCID: PMC5475350.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Alfonso Martínez Fernández Reyes